Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial
Status:
Suspended
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A total of 46 patients diagnosed with liver cirrhosis will be recruited. All patients will be
evaluated with five psychometric tests and critical flicker frequency to diagnosis minimal
hepatic encephalopathy (MHE). A breath test sample will be performed in all patients with MHE
with 10 g of lactulose to establish the diagnosis of small intestinal bacterial overgrowth
(SIBO). Patients diagnosed with EHM and SIBO will be randomized to receive per day 1200 mg of
rifaximin (group A) or placebo (group B) for 2 weeks. A complete medical history, nutritional
assessment, biochemical studies, and evaluation of quality of life will be performed in all
patients included in the study. Besides the initial visit, patients will receive subsequent
care 2, 4, 8, 12, and 24 weeks after the beginning of the study.